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Background: Interactions with the pharmaceutical in-
dustry are known to affect the attitudes and behaviors
of medical residents; however, to our knowledge, a na-
tionally representative description of current practices has
not been reported.
Methods: The Association of Program Directors in In-
ternal Medicine surveyed 381 US internal medicine resi-
dency program directors in 2006-2007 regarding phar-
maceutical industry support to their training programs.
The primary outcome measure was program director re-
port of pharmaceutical financial support to their resi-
dency. Demographic and performance variables were ana-
lyzed with regard to these responses.
Results: In all, 236 program directors (61.9%) re-
sponded to the survey. Of these, 132 (55.9%) reported
accepting support from the pharmaceutical industry. One
hundred seventy of the 236 program directors (72.0%)
expressed the opinion that pharmaceutical support is
not desirable. Residency programs were less likely to
receive pharmaceutical support when the program di-
rector held the opinion that industry support was not ac-
ceptable (odds ratio [OR], 0.07; 95% confidence inter-
val [CI], 0.02-0.22). Programs located in the southern
United States were more likely to accept pharmaceuti-
cal support (OR, 8.45; 95% CI, 1.95-36.57). The Ameri-
can Board of Internal Medicine pass rate was inversely
associated with acceptance of industry support: each 1%
decrease in the pass rate was associated with a 21% in-
crease in the odds of accepting industry support (OR, 1.21;
95% CI, 1.07-1.36).
Conclusions: Although most of the program directors
did not find pharmaceutical support desirable, more than
half reported acceptance of industry support. Accep-
tance of pharmaceutical industry support was less preva-
lent among residency programs with a program director
who considered support unacceptable and those with
higher American Board of Internal Medicine pass rates.
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O VER THE PAST 2 DECADES,the impact of pharma-ceutical industry market-ing on the professional-ism and prescribing
practices of physicians has gained na-
tional media attention. In response to this
concern, several professional organiza-
tions, including the American Medical As-
sociation,1 the Association of American
Medical Colleges,2 and the American Col-
lege of Physicians3 have issued guide-
lines for appropriate relationships be-
tween physicians and the pharmaceutical
industry.4 Because residency training rep-
resents a particularly formative time for
physicians, the Accreditation Council for
Graduate Medical Education (ACGME) is-
sued its own guidelines in 2002.5
Previous studies have shown that con-
tact with pharmaceutical company repre-
sentatives is common and may influence
resident attitudes and behaviors.6-10 Com-
pany sales visits and industry-sponsored
conferences may lead to changes in resi-
dent prescribing practices, which are not
always consistent with evidence-based rec-
ommendations.9,11-13 Residents often do not
believe that their own actions are influ-
enced by industry contact8,14-16 or gifts,8,15,17
but they believe that their colleagues’ pre-
scribing practices could be altered.15 Resi-
dency programs have sought to address
this potential conflict of interest through
the development of curricula and guide-
lines that outline appropriate residency-
industry interactions.18
In 2006, Brennan et al,19 on behalf of the
American Board of Internal Medicine
(ABIM) and Institute on Medicine as a Pro-
fession, proposed that academic medical
centers more strongly regulate their inter-
actions with industry to eliminate existing
conflicts of interest. In the intervening years,
individual medical institutions have en-
acted stronger policies,20 and a task force
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report that called for the prohibition of all industry gifts
to physicians was endorsed by the Association of Ameri-
can Medical Colleges.2 The recent report by the Ameri-
can Medical Association’s Council on Ethical and Judi-
cial Affairs, which recommended against acceptance of
any industry funding to support medical education,1 was
met with greater discussion and particular concern re-
garding the loss of funding. Most recently, the Institute
of Medicine concluded that “ . . . industry financial re-
lationships do not benefit the educational missions of
medical institutions in ways that offset the risks cre-
ated.”21(p123) Despite such attention, a nationally repre-
sentative description of the current landscape of phar-
maceutical industry support to residency programs is not
known. The attitudes and practices of program leader-
ship could provide insight into the current momentum
for change, the degree to which programs have already
adopted new recommendations, and possible barriers to
further implementation of policies.
The objectives of this study were to assess (1) the cur-
rent attitudes of program directors regarding pharma-
ceutical industry support of internal medicine resi-
dency program activities, (2) the practices of internal
medicine residency programs with regard to acceptance
of industry support, and (3) potential associations be-




The Survey Committee of the Association of Program Directors
in Internal Medicine is charged with developing questionnaires
to track characteristics of internal medicine residency programs
in the United States, as well as to address current issues facing
residency programs and residency program directors. In Novem-
ber 2006, an e-mail notification with a program-specific hyper-
link to a Web-based questionnaire was sent to each of the 381
member programs of the Association of Program Directors in In-
ternal Medicine, representing 98.2% of the 388 US categorical in-
ternal medicine residency programs.22 Subsequent e-mail re-
quests were sent in December 2006 and January 2007.
Residency program directors were asked whether their pro-
grams accept support of any kind from the pharmaceutical in-
dustry. Those who responded yes were asked to identify spe-
cific forms of support, including food for conferences,
educational materials, office supplies, drug samples, and un-
restricted educational funds, as well as types of industry in-
volvement, such as direct contact with residents (off-site and
on-site). Program directors were also asked why the residency
program accepts pharmaceutical support. Data were collected
on several variables hypothesized to have an association with
acceptance of pharmaceutical support. Information regarding
the residency programs included sponsor type, ownership of
the primary teaching hospital, program size, number of hos-
pital beds, employment of hospitalists, number of associate pro-
gram directors, accreditation cycle length, presence of formal
guidelines for industry interactions, existence of resident cur-
riculum on appropriate interactions, percentage of faculty de-
fined by primary academic appointment, and percentage of ap-
proved positions filled by international medical graduates.
Program director characteristics included the number of years
in their position, their academic rank, their salary, their sub-
specialty, whether they had the final decision regarding ac-
cepting support, and their opinion on accepting industry sup-
port. Before the program identities were blinded for analysis,
the programs were assigned to a region based on US Census
Bureau assignments,23 and the ABIM 3-year rolling (ie, aver-
age) pass rate was obtained for each program from the ABIM
Web site.24 This study was approved by the Mayo Foundation
Institutional Review Board.
DATA ANALYSIS
The survey included 4 categories of program director opin-
ion, which were further grouped for analysis. The “never
acceptable” group reflects those who answered that pharma-
ceutical industry support was “ . . . not desirable and should
not be accepted in any case,” and the “acceptable” group
included those who answered “ . . . desirable and should be
encouraged” or “ . . . not desirable, but acceptable when
other sources not available” or “other.” Those who answered
“other” were included in this second group because review
of the additional comments indicated that all believed sup-
port was acceptable to varying degrees, with differing levels
of oversight and restrictions. This dichotomous representa-
tion for opinion was used in the logistic regression models
described in the next paragraph.
Both univariate (unadjusted) and multivariate (adjusted)
logistic regression models were used to describe the relation-
ship between the probability of accepting pharmaceutical
industry support and the available covariates. Covariates
with variance inflation factors greater than 2.5 were
excluded from the adjusted model because of concerns
regarding multicollinearity in logistic regression models.25
The continuous variables included in the adjusted model
were inspected for linearity in the logit using design vari-
ables.26 Variables deemed to violate the linearity assumption
were categorized before inclusion in the final adjusted
model. All 2-way interactions between covariates were then
assessed for significance.
Finally, 2 sets of odds ratio (OR) estimates, along with cor-
responding confidence intervals (CIs) and P values, were cal-
culated using the unadjusted (univariate) models for each co-
variate separately as well as the final adjusted (multivariate)
model, which included all covariates simultaneously. To ac-
count for multiple comparisons, a conservative  level of .01
was used to determine statistical significance throughout. All
calculations were performed by one of us (A.J.H.) using SAS
statistical software (version 9.1; SAS Institute Inc, Cary, North
Carolina).
RESULTS
Surveys were returned by 236 programs (61.9%).27 Among
respondents, their geographic distribution, number of resi-
dents per program, and ABIM pass rates were similar to
those seen nationally.23,24,28,29 One hundred thirty-two pro-
grams (55.9%) reported accepting some kind of support
from the pharmaceutical industry. A summary of all the
covariates considered and their association with accept-
ing industry support is presented in Table 1 and
Table 2.
The forms of industry support and types of interac-
tions allowed by programs accepting support are listed
in Table 3. The most common forms of industry sup-
port included food for conferences (90.9%), educa-
tional materials (83.3%), office supplies (68.9%), and drug
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OR P Value OR P Value
ACGME cycle length
4 y 123 (52.1) 50.4 0.66 .14 0.91 .86
4 yc 98 (41.5) 61.2
No answer 15 (6.4) 6.7
Employment of hospitalists
Yes 182 (77.1) 53.3 0.46 .03 0.65 .51
Noc 49 (20.8) 69.4
No answer 5 (2.1) 20.0
Extra associate program directorsd
Yes 119 (50.4) 54.6 0.84 .53 1.98 .24
Noc 96 (40.7) 58.3
No answer 21 (8.9) 52.4
Final decision on accepting support
Program director 112 (47.5) 54.5 0.81 .46 0.53 .22
Otherc 112 (47.5) 58.9
No answer 12 (5.1) 41.7
Formal guidelines for interactions
Yes 153 (64.8) 56.9 0.96 .88 0.79 .71
Noc 67 (28.4) 58.2
No answer 16 (6.8) 37.5
Geographic region
West 30 (12.7) 63.3 2.29 .08 2.88 .26
South 59 (25.0) 72.9 3.88 .001 8.45 .005
Midwest 54 (22.9) 44.4 0.96 .92 0.97 .96
Northeastc 76 (32.2) 47.4
Unknown 17 (7.2) 58.8
International medical graduates, %
35 48 (20.3) 56.3 1.22 .66 0.20 .10
25 to 35 42 (17.8) 59.5 1.41 .45 0.69 .69
10 to 25 41 (17.4) 61.0 1.61 .31 0.28 .15
0 to 10 45 (19.1) 53.3 1.14 .77 0.46 .34
0c 40 (16.9) 50.0
No answer 20 (8.5) 55.0
Ownership of primary teaching hospital
University 33 (14.0) 51.5 0.84 .66 0.72 .68
State/municipal 29 (12.3) 58.6 1.14 .75 1.05 .95
Other 27 (11.4) 63.0 1.40 .45 0.68 .65
Private, nonprofitc 140 (59.3) 55.0
No answer 7 (3.0) 57.1
Primary sponsoring institution
Medical school 63 (26.7) 60.3 1.19 .58 1.83 .36
Other 36 (15.3) 50.0 0.77 .48 2.08 .33
Hospitalc 130 (55.1) 55.4
No answer 7 (3.0) 57.1
Program director opinione
Never acceptable 66 (28.0) 22.7 0.11 .001 0.07 .001
Acceptablec 158 (66.9) 69.6
No answer 12 (5.1) 58.3
Program director salary, $
175 000 92 (39.0) 62.0 1.48 .17 0.57 .31
175 000c 125 (53.0) 52.8
No answer 19 (8.1) 47.4
Program director subspecialty
Traditional GIM 118 (50.0) 58.5 1.03 .92 1.20 .71
Otherc 118 (50.0) 53.4
Resident curriculum
Yes 69 (29.2) 53.6 0.84 .55 0.50 .21
Noc 153 (64.8) 58.8
No answer 14 (5.9) 35.7
Abbreviations: ACGME, Accreditation Council for Graduate Medical Education; GIM, general internal medicine; OR, odds ratio.
aBecause of rounding, percentages may not total 100.
bMultivariate logistic regression accounting for all variables in Tables 1 and 2.
cOdds ratio reference group.
dHaving more associate program directors than the ACGME requires for programs of their size.30
eThe 4 choices given on the survey were further grouped for analysis, with “never acceptable” reflecting those who answered “. . .not desirable and should not
be accepted in any case,” and “acceptable” reflecting those who answered “. . .desirable and should be encouraged” or “. . .not desirable but acceptable when
other sources not available” or “other.” Those who answered “other” added comments reflecting that support was acceptable to varying degrees, with differing
levels of oversight and restrictions.
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samples (57.6%). Among programs that accept industry
support, many reported allowing direct off-site contact
with residents (74.2%) and more than one-third re-
ported direct on-site contact (40.2%).
Of the 132 programs that accepted industry support,
92 (69.7%) cited a lack of other funding sources as a rea-
son for acceptance. Other reasons included popularity
with residents (40.9%), important educational value other
than financial support (28.0%), ease of attainment
(26.5%), and being encouraged by the department chair
or administration to accept the support (19.7%). Seventy-
nine programs (59.8%) indicated more than 1 reason for
accepting industry support.
One hundred seventy program directors (72.0%)
reported an opinion that industry support was not
desirable. The Figure displays the prevalence of
industry support across the various program director
opinions regarding it. The proportion accepting indus-
try support was much lower among programs with a
program director who believed it was unacceptable
(22.7%) than among programs with a director who
believed this support was desirable (72.7%) or not
desirable but acceptable (71.2%). The significance of
the relationship between program director opinion
and acceptance is supported by a Pearson 2 test of
independence (P .001).
The final decision to accept support was left to the
program director’s discretion 50% of the time. Other
final decision makers included the chair of medicine,
the hospital administrator, or an institutional over-
sight committee. To address potential influence from
the pharmaceutical industry, 153 programs (64.8%)
had established formal written guidelines, whereas
only 69 (29.2%) had implemented a specific curricu-
lum to educate residents on these interactions.
Separate univariate logistic regression models for
acceptance of industry support and each program vari-
able indicated 3 covariates associated with acceptance:
ABIM rolling pass rate, program director opinion, and
geographic region. When we included all variables
under consideration (as listed in Tables 1 and 2) in a
multivariate logistic regression model, the adjusted
ORs for these 3 covariates remained significant (all
P  .005). Program director academic rank was
excluded from the final adjusted model because of a
high variance inflation factor. The percentage of
approved positions filled by international medical
graduates appeared to be nonlinear in the logit; thus,
Table 2. Quantitative Program Characteristics and Odds of Accepting Industry Support Among 236 Internal Medicine
Residency Programs
Characteristic Median (Mean) [Range]
Unadjusted Adjusteda
ORa P Value ORb P Value
ABIM 2004-2006 rolling pass rate, % 94 (92.8) [68-100] 1.12 .001 1.21 .002
ACGME-approved positions, No. 39 (50.7) [7-213] 1.01 .13 1.00 .87
Beds in teaching hospital, No. 489 (501.8) [57-1500] 1.00 .25 1.00 .65
Program director tenure, y 6 (7.2) [0-30] 0.97 .28 0.96 .32
Faculty with a primary academic appointment, % 80 (64.3) [0-100] 1.01 .16 1.00 .89
Abbreviations: ABIM, American Board of Internal Medicine; ACGME, Accreditation Council for Graduate Medical Education; OR, odds ratio.
aMultivariate logistic regression accounting for all variables in Tables 1 and 2.
bOdds ratio for a 1-unit decrease in the continuous variable.
Table 3. Forms of Industry Support and Interactions Among
132 Programs Accepting Supporta
No. (%) Accepting
Support
Food for conferences 120 (90.9)
Educational materials 110 (83.3)
Office supplies 91 (68.9)
Drug samples for clinics 76 (57.6)
Unrestricted education funds 72 (54.5)
Funds for food 37 (28.0)
Other funds 14 (10.6)
Interactions
Direct contact, off-site 98 (74.2)
Direct contact, on-site 53 (40.2)
Access to contact information 2 (1.5)
aOnly program directors who indicated that their program accepted
support from the pharmaceutical industry were asked these follow-up






















































Figure. Internal medicine residency program acceptance of pharmaceutical
industry support according to the opinions of 236 program directors.
Because of rounding, program director opinion group percentages may not
total 100.
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it was categorized into 5 groups by quintiles before
inclusion in the final adjusted model. None of the
2-way interactions were found to be statistically sig-
nificant. For each 1% decrease in the ABIM pass rate,
the odds of accepting support increased by 21% (OR,
1.21; 95% CI, 1.07-1.36). As anticipated, residency
programs were far less likely to receive pharmaceutical
support when the program director held the opinion
that industry support was “never acceptable” (OR,
0.07; 95% CI, 0.02-0.22). Programs located in the
southern United States were more likely to accept
pharmaceutical support (OR, 8.45; 95% CI, 1.95-
36.57) compared with those in the northeastern
United States.
COMMENT
Most internal medicine residency program directors
do not find acceptance of support from the pharma-
ceutical industry desirable. At the same time, more
than half of the program directors oversaw residency
programs that accepted pharmaceutical industry fund-
ing. Acceptance of support from the pharmaceutical
industry remains common among internal medicine
residency programs but has decreased substantially. At
a time when concern about pharmaceutical involve-
ment in training programs was just gaining momen-
tum, 88.6% of internal medicine program directors
surveyed in 1990 reported industry support of some
kind31 compared with 55.9% of the current programs.
Even in the extremely unlikely case that all nonre-
sponding programs in our study accepted industry
support, the percentage of the 381 programs accepting
it would be just 72.7%, still a 16.3% decrease since the
1990 study by Lichstein et al,31 indicating that our
finding of decreased acceptance of pharmaceutical
support is real. This change in practice may have
resulted from the additional guidelines and publicity
that have surrounded this topic in the intervening
years.3,19,20,32
In earlier studies, the majority of residency program
leadership indicated that the benefits of pharmaceutical
company representatives outweighed any negative re-
sults.31,33 Our survey found that only 15.7% of all re-
sponding program directors reported acceptance of in-
dustry support because of its nonfinancial educational
value. This low number may be due to the increasing evi-
dence of pharmaceutical industry influence on physi-
cian practices and a concomitantly growing skepticism
among program directors regarding the objectivity of in-
formation from pharmaceutical representatives.9,11-13 The
ACGME has recognized that industry interactions can
conflict with the educational goals set forward by the 6
general competencies,5 and the Association of Ameri-
can Medical Colleges recently proposed that academic
medical centers prohibit acceptance of all gifts and re-
strict access by pharmaceutical representatives.2 The dis-
crepancy between the number of program directors who
accept industry support (55.9%) and the number who
believe it is of educational value (15.7%) identifies a gap
that is worthy of further study.
Pharmaceutical industry support is accepted by
some residency programs with a program director who
did not consider this practice desirable. Several rea-
sons may account for this disconnect. Programs may
find industry support a readily available funding
source for specific activities. For example, the most
commonly cited use of industry funding was for provi-
sion of food at conferences or educational activities, a
strategy that has been shown to boost conference
attendance.34 In addition, residency program practices
may not always reflect the opinion of the program
director because directors had the final say regarding
acceptance of industry support at only 50% of the
institutions. Nonetheless, the opinion of the program
director regarding the appropriateness of industry sup-
port was the strongest indicator of actual acceptance,
suggesting that program leadership may have the best
opportunity to further define appropriate industry-
residency interactions.
Despite the attention around conflict of interest with
pharmaceutical support, we were surprised to find that
only 29.2% of the responding program directors re-
ported a specific curriculum to instruct residents about
interactions with the pharmaceutical industry. We found
no statistically significant association between resi-
dency acceptance of pharmaceutical support and the pres-
ence of a formal curriculum to educate residents about
appropriate interactions. In 2002, the ACGME recom-
mended curricula to educate residents regarding the poli-
cies of their specific institutions and published guide-
lines. Nonetheless, trainees are often unaware of the
position of their own institution.14,35 We found that the
number of institutions with a formal policy regarding
appropriate interactions has nearly doubled from
35.3% in 199031 to 64.8% in the current survey. We
did not find a significant association between the pres-
ence of a policy statement and program refusal of
industry support, suggesting that these policies stop
short of restricting all interaction but rather set
boundaries for what the individual institutions believe
are appropriate. Future study of the different guide-
lines of individual programs may elucidate how poli-
cies influence practices.
Our finding of an inverse relationship between a
program’s ABIM pass rate and acceptance of pharma-
ceutical funding supports an earlier observation.
Wolfsthal et al36 identified this same association when
looking at benchmarks of residency program financial
support and their correlation with quality measures.
The ABIM pass rate is one indicator of program qual-
ity. The need or desire for pharmaceutical support
could be a marker for lower institutional support for
the educational mission. The association of ABIM pass
rate and pharmaceutical support is worthy of further
study because ABIM pass rates have been associated
with other ACGME competencies. For instance,
higher performance on the ABIM certification exami-
nation has been associated with markers of profession-
alism.37 Because potential conflicts of interest that
arise with pharmaceutical support may reflect on com-
ponents of professionalism, further study into the rela-
tionships between professionalism, ABIM pass rates,
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and training environments where pharmaceutical sup-
port is accepted warrant further investigation.
We recognize specific limitations to our study as
well as opportunities for future work. Responses were
obtained through a volunteer survey, and it is possible
that the residency programs of respondents differ from
those who did not complete the survey. However,
among respondents, their geographic distribution, the
number of residents per program, and the program’s
ABIM pass rates were similar to those seen nation-
ally.23,24,29 Although we identified the prevalence of
accepting pharmaceutical support among internal medi-
cine residency programs, the degree to which programs
rely on pharmaceutical funding for residency activities
requires clarification. The evolving attitudes, policies,
and practices of internal medicine residency programs
should be tracked in the face of new and more restric-
tive recommendations from various medical societies.
Although we observed an association between higher
ABIM pass rates and not accepting industry support,
our study was not designed to demonstrate a causal
relationship and warrants further investigation as
already noted. Finally, the significant association
between geographic region and acceptance of pharma-
ceutical support is not well understood and provides an
opportunity for further exploration.
In addition to the important influence of program di-
rectors, residency program practices are likely affected
by institutional history, available financial support, and
the culture within individual academic environments. The
influence of pharmaceutical industry support on medi-
cal education warrants further investigation. Although
all of the underlying reasons are not yet fully eluci-
dated, it is clear that, in the face of attention around con-
flict of interest with pharmaceutical support, internal
medicine residency program directors have taken a less
permissive stance and acceptance of industry funding has
declined. Nevertheless, more than half of the residency
programs surveyed continue to accept some form of in-
dustry support.
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